1
st
-line nab-paclitaxel + gemcitabine in advanced PC: Real-life
data from Italy (multicentre, retrospective analysis)
•
Patients received
1cycle of nab-P (100/125
mg/m
2
) + gem (1000 mg/m
2
) as 1
st
-line treatment
for PC
•
N=208; median (range) age, 67 (37-86) years;
ECOG PS 0, 45.2%; 1, 37%; and 2, 17.8%
•
Median OS, 11.3 months
(95% CI: 9.337-11.236
months);
median PFS, 6.7 months
(95% CI: 6.197-
7.203 months)
•
Treatment was safe and manageable; only 4
patients discontinued due to unacceptable toxicity
•
Reduction in CA19-9 of
50% from baseline
appeared to be a good prognostic indicator
•
High NLR (>5) and LDH were related to poor PFS
and a worse outcome
Giordano et al. ECC 2015, abstract 2334
This study confirms the efficacy and safety
of nab-P + gem as 1
st
-line treatment in a
real-life, unselected patient population
Overall survival
0.0
Proportion of survival
OS (months)
36.0
18.0
42.0 48.0
0.2
0.4
0.6
1.0
0.8
Survival function
Censored
0.0 6.0 12.0
24.0 30.0
0.0
Proportion of survival
PFS (months)
18.0
9.0
21.0 24.0
0.2
0.4
0.6
1.0
0.8
Survival function
Censored
0.0 3.0 6.0
12.0 15.0
43%
12%
Progression-free survival
